Communication about adherence to long-term antipsychotic prescribing: an observational study of psychiatric practice.

Soc Psychiatry Psychiatr Epidemiol

Centre for Quality Improvement, Royal College of Psychiatrists, 4th Floor Standon House, 21 Mansell Street, London, E1 8AA, UK.

Published: April 2013

Purpose: Partial or non-adherence is common in people taking antipsychotic medication. A good therapeutic alliance is thought by psychiatrists to encourage engagement with a service and improve adherence. This paper aims to examine how psychiatrists and patients communicate in outpatient consultations about partial or non-adherence to antipsychotic prescribing.

Methods: Ninety-two outpatient consultations involving patients prescribed antipsychotic medication and their psychiatrists were tape recorded. Parts of consultations where partial/non-adherence to antipsychotic medication was discussed were analysed using conversation analysis.

Results: In 22 (24 %) consultations, partial/non-adherence was disclosed. Most commonly, it was volunteered without prompting and was more likely to be presented as a deliberate choice than omission by the patient. Psychiatrists responded to all but one disclosure, and patients delivered their reports in ways that minimised the prospect of this response being disciplinary. The most common outcome was a change in prescribing: a medication omission, swap or dosage reduction.

Conclusions: Patients and psychiatrists work together to create a safe conversational environment in which to discuss this potentially difficult issue. Unlike previous studies of patient reports of psychotic symptoms and side effects of drowsiness being ignored, psychiatrists nearly always respond to disclosures of partial/non-adherence. Psychiatrists should apply the same listening skills to patients' disclosures of troubling side effects and psychotic symptoms.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00127-012-0581-yDOI Listing

Publication Analysis

Top Keywords

antipsychotic medication
12
partial non-adherence
8
outpatient consultations
8
consultations partial/non-adherence
8
psychotic symptoms
8
side effects
8
psychiatrists
7
antipsychotic
5
communication adherence
4
adherence long-term
4

Similar Publications

Basic Science and Pathogenesis.

Alzheimers Dement

December 2024

Department of Pharmacology, Central University of Punjab, Bathinda, Bathinda, Punjab, India.

Background: In previous studies, we found that quetiapine activates the AKT signaling which further inhibits the action of GSK3β. Quetiapine has been reported to possess neuroprotective potential in schizophrenia and other neurodegenerative models.

Method: On day 1 and 3, rats received bilateral intracerebroventricular (i.

View Article and Find Full Text PDF

Clinical Manifestations.

Alzheimers Dement

December 2024

Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Background: Psychotropic medications are commonly prescribed for behavioral and psychological symptoms of dementia (BPSD). However, the safety of antipsychotic drugs has always been a concern. The study aims to investigate the relationship between brain structural and the effective dosage of antipsychotic drugs.

View Article and Find Full Text PDF

Clinical Manifestations.

Alzheimers Dement

December 2024

Mental Health Center, West China Hospital, Sichuan University, Chengdu, China.

Background: Behavioral and psychological symptoms of dementia (BPSD) are highly prevalent in people living with dementia. Atypical antipsychotics (AAPs) are commonly used to treat BPSD, but their comparative efficacy and acceptability are unknown.

Methods: This study was conducted following the guidelines of the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA).

View Article and Find Full Text PDF

Background: Dementia is associated with a range of non-cognitive features that can occur during the prodromal phase. Improved recognition of non-cognitive presentations of dementia could reduce inequalities in dementia diagnosis, particularly if sociocultural factors influence rates of help-seeking for cognitive symptoms. We aimed to investigate presentations to primary care in the years before dementia diagnosis in a deprived and ethnically diverse population with universal access to health care.

View Article and Find Full Text PDF

Clinical Manifestations.

Alzheimers Dement

December 2024

PO Box 210242, Tucson, AZ, USA.

Background: Neuropsychiatric disorders including depression, insomnia, epilepsy, schizophrenia, and attention-deficit and hyperactivity disorder (ADHD) have been associated with a neurodegenerative process and linked to increased risk for Alzheimer's Disease (AD). Because of the shared biological mechanisms of AD and neuropsychiatric disorders, we hypothesized that pharmacologic treatment for neuropsychiatric disorders could impact the risk for AD. CNS drugs that are first-line therapies for neuropsychiatric disorders (including antidepressants, sedatives, anticonvulsants, antipsychotics, and stimulants) were investigated for impact on AD incidence.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!